O-GlcNAc transferase regulates glioblastoma acetate metabolism via regulation of CDK5-dependent ACSS2 phosphorylation

Lorela Ciraku,Zachary A. Bacigalupa,Jing Ju,Rebecca A. Moeller,Giang Le Minh,Rusia H. Lee,Michael D. Smith,Christina M. Ferrer,Sophie Trefely,Luke T. Izzo,Mary T. Doan,Wiktoria A. Gocal,Luca D’Agostino,Wenyin Shi,Joshua G. Jackson,Christos D. Katsetos,Kathryn E. Wellen,Nathaniel W. Snyder,Mauricio J. Reginato
DOI: https://doi.org/10.1038/s41388-022-02237-6
IF: 8.756
2022-02-22
Oncogene
Abstract:Glioblastomas (GBMs) preferentially generate acetyl-CoA from acetate as a fuel source to promote tumor growth. O-GlcNAcylation has been shown to be elevated by increasing O-GlcNAc transferase (OGT) in many cancers and reduced O-GlcNAcylation can block cancer growth. Here, we identify a novel mechanism whereby OGT regulates acetate-dependent acetyl-CoA and lipid production by regulating phosphorylation of acetyl-CoA synthetase 2 (ACSS2) by cyclin-dependent kinase 5 (CDK5). OGT is required and sufficient for GBM cell growth and regulates acetate conversion to acetyl-CoA and lipids. Elevating O-GlcNAcylation in GBM cells increases phosphorylation of ACSS2 on Ser-267 in a CDK5-dependent manner. Importantly, we show that ACSS2 Ser-267 phosphorylation regulates its stability by reducing polyubiquitination and degradation. ACSS2 Ser-267 is critical for OGT-mediated GBM growth as overexpression of ACSS2 Ser-267 phospho-mimetic rescues growth in vitro and in vivo. Importantly, we show that pharmacologically targeting OGT and CDK5 reduces GBM growth ex vivo. Thus, the OGT/CDK5/ACSS2 pathway may be a way to target altered metabolic dependencies in brain tumors.
oncology,genetics & heredity,biochemistry & molecular biology,cell biology
What problem does this paper attempt to address?